Isolation and Characterisation of Candida Species From Post- Renal Transplant Recipients with Urinary Tract Infection with Special Reference to Echinocandins by Arthy, G
 ISOLATION AND CHARACTERISATION OF CANDIDA SPECIES 
FROM  POST- RENAL TRANSPLANT RECIPIENTS WITH 
URINARY TRACT INFECTION WITH SPECIAL REFERENCE TO 
ECHINOCANDINS 
 
 
Dissertation submitted for 
M.D. MICROBIOLOGY BRANCH – 1V 
DEGREE EXAMINATION 
 
 
 
THE TAMILNADU DR.M.G.R.MEDICAL UNIVERSITY 
CHENNAI – 600 032 
TAMILNADU 
 
 
MAY 2019 
  
 
 
CERTIFICATE 
 
 
 This is to certify that this dissertation titled “ISOLATION AND 
CHARACTERISATION OF CANDIDA SPECIES FROM POST- RENAL 
TRANSPLANT RECIPIENTS WITH URINARY TRACT INFECTION 
WITH SPECIAL REFERENCE TO ECHINOCANDINS” is a bonafide record 
of work done by Dr.G.ARTHY, during the period of March 2017 to February 
2018 under the guidance of Prof.Dr.R.VANAJA M.D., Professor of 
Microbiology, Institute of Microbiology , Madras Medical College and Rajiv 
Gandhi Government General Hospital, Chennai - 600003, in partial fulfillment of 
the requirement of M.D. MICROBIOLOGY Degree Examination of The 
Tamilnadu  Dr.M.G.R. Medical University to be held in May 2019. 
 
 
 
 
 
 
Dr.R.JAYANTHI, M.D.FRCP (Glas) 
DEAN 
Madras Medical College & 
Rajiv Gandhi Govt. General Hospital, 
Chennai – 600003. 
Dr.J.EUPHRASIA LATHA, 
    M.D.DGO 
Director, 
Institute of Microbiology 
Madras Medical College & 
Rajiv Gandhi Govt. General Hospital, 
Chennai – 600003. 
 
  
DECLARATION 
 
 
 I, Dr.G.ARTHY, Post Graduate , Institute of Microbiology, Madras 
Medical College, solemnly declare that the dissertation titled “ISOLATION 
AND CHARACTERISATION OF CANDIDA SPECIES FROM POST- 
RENAL TRANSPLANT RECIPIENTS WITH URINARY TRACT 
INFECTION WITH SPECIAL REFERENCE TO ECHINOCANDINS”is the 
bonafide work done by me at Institute of Microbiology, Madras Medical College 
under the expert guidance and supervision of Prof.Dr.R.VANAJAM.D., 
Professor, Institute of Microbiology, Madras Medical College. The dissertation is 
submitted to the Tamil Nadu Dr.M.G.R Medical University towards partial 
fulfillment of requirement for the award of M.D., Degree (Branch IV) in 
Microbiology. 
 
 
 
 
 
Place: Chennai 
 
Date:                            Dr.G.ARTHY 
 
 
 
 
 
 
Signature of the Guide 
 
Prof. Dr.R.VANAJA, MD., 
Professor, 
Institute of Microbiology 
Madras Medical College, Chennai-600 003. 
  
ACKNOWLEDGEMENTS 
 
 
 I wish to express my sincere thanks to Dr.R.Jayanthi, M.D.FRCP (Glas) 
Dean, Rajiv Gandhi Government General Hospital & Madras Medical College, 
Chennai-3 for permitting me to use the resources of this institution for my study. 
 
I express my thanks to Dr.J.Euphrasia latha, M.D.DGO, Director, 
Institute of Microbiology for her guidance and support. 
 
 Sincere thanks to Former Professor Dr.Mangala Adisesh M.D., Institute 
of Microbiology for her constant encouragement and support during this work. 
 
 I owe my heartfelt gratitude and sincere thanks to my guide Dr.R.Vanaja, 
M.D.,Professor, Institute of Microbiology for  her valuable suggestions, 
guidance,constant support, motivation and encouragement throughout this study. 
 
          My Sincere thanks to Professor Dr.N.Gopalakrishnan 
M.D.,D.M.,MRCP(UK)FRCP, Director , Institute of Nephrology  and Professor 
Dr.C.Ilamparuthi.M.S,M.CH,.D.N.B,F.I.C.S(URO)Director, Institute of 
Urology  for his constant encouragement and support during my study. 
 
 I would like to thank all my Professors Dr.S.Thasneem Banu M.D., 
Dr.U.Umadevi M.D., and  Dr.C.P.Ramani M.D., for their support during this 
study.  
         I extend my gratitude to my co-guide Dr.R.Kesavan M.D.DCH .,Assistant 
Professor, Institute of Microbiology for his valuable guidance and constant 
support in this study. 
 
 I extend my gratitude to   my former co-guide Dr.N.RathnaPriya 
M.D.,Senior Assistant Professor, Institute of Microbiology for her valuable 
guidance and constant support in this study. 
 
 I wish to extend my thanks to our Assistant ProfessorsDr.Lakshmipriya.N 
M.D.DCH., Dr.K.G.Venkatesh M.D., Dr.P.Shanmugapriya M.D., 
Dr.C.Nithya M.D., Dr.J.PadmaKumari M.D., Dr.S.Vinotha M.D.,  Dr. 
B.Gomathi Manju M.D.,  for their support. 
 
 I wish to extend my thanks to our  formerAssistant Professors Dr.Deepa.R 
M.D., Dr.K.Ushakrishnan M.D., Dr.Sripriya.C.S M.D., Dr. David Agatha 
M.D., Dr.B.Natesan M.D.DLO., for their support. 
 
 I would like to extend my thanks to all my postgraduate colleagues and 
technicians for their constant support and help in this study. 
 
 I am thankful to my dear parents, inlaws for their unconditioned love, 
sacrifice and constant emotional support. I thank my husband 
Dr.N.RaghuramanM.D.,for his constant motivation, emotional support and help 
in  completing the dissertation work.   
 
 I would like to thank the Institutional Ethics Committee ,Madras Medical 
college for approving my study . 
 
     Last but not least, I would like to thank the patients participated in this 
study for their co-operation and support. 
  
 
TABLE OF CONTENTS 
 
Sl. 
No. TITLE Page No. 
1 INTRODUCTION 1 
2 AIMS & OBJECTIVES 3 
3 REVIEW OF LITERATURE 4 
4 MATERIALS & METHODS 42 
5 RESULTS 55 
6 DISCUSSION 70 
7 SUMMARY 75 
8 CONCLUSION 77 
9 COLOUR PLATES 78 
10 BIBLIOGRAPHY  
 
APPENDIX- I  ABBREVIATIONS 
 
APPENDIX- II  STAINS, REAGENTS, MEDIA  
 
ANNEXURE - I    CERTIFICATE OF APPROVAL 
 
ANNEXURE - II   PROFORMA  
 
ANNEXURE - III   PATIENTS CONSENT FORM 
 
ANNEXURE - IV  INFORMATION SHEET 
 
ANNEXURE - V  MASTER CHART 
 
 
  
LIST OF TABLES 
 
Sl. 
No TITLE Page No. 
1 Definition and Diagnostic criteria  of  Urinary  tract Infection 19 
2 Classification  of  Urinary  tract Infection . 21 
3 Identification of Candida species by  Chromogenic agar medium. 49 
4 Identification of Candida species by Sugar  Fermentation test  . 50 
5 Identification of Candida species by  Sugar Assimilation test. 51 
6 Antifungal panel for Candida species as per CLSI guidelines and  their Interpretive  Criteria. 53 
7 Age wise  distribution  of  Post  Renal  Transplant patients. 56 
8 Genderwise  distribution  of  Post  Renal  Transplant patients. 57 
9 Distribution  of Post  Renal  Transplant patients  according to donors. 58 
10 
A)  : Distribution of culture  positivity in  urine  samples  
collected  during  the  follow  up  visits  in  Post  Renal  
Transplant  recipients 
59 
B): Distribution  of  Culture  positivity   according  to  
gender 59 
11 Distribution  of Asymtomatic/symptomatic  Candiduria  among Post  Renal  Transplant  recipients 60 
12 Distribution of Candida  isolates from Post Renal Transplant recipients 61 
13 
Antifungal Susceptibility  Pattern of Candida  albicans  
isolates from urine samples of Post Renal Transplant 
recipients 
63 
 
  
  
Sl. 
No TITLE Page No. 
14 
Antifungal Susceptibility  Pattern of Candida  glabrata  
isolates from urine samples of Post Renal Transplant 
recipients 
64 
15 
Antifungal Susceptibility  Pattern of Candida  krusei 
isolates from urine samples of Post Renal Transplant 
recipients 
65 
16 
Antifungal Susceptibility  Pattern of Candida  tropicalis 
isolates from urine samples of Post Renal Transplant 
recipients 
66 
17 
Antifungal Susceptibility  Pattern of Candida  parapsilosis 
isolates from urine samples of Post Renal Transplant 
recipients 
67 
18 Biofilm producers and  Non biofilm producers among Candida  isolates from Post Renal Transplant recipients 68 
19 Antifungal resistance   Pattern  among  Candida   isolates from samples of Post Renal Transplant recipients 69 
 
  
LIST OF FIGURES 
 
Sl. 
No. TITLE Page No. 
1 Agewise  distribution  of  Post  Renal  Transplant patients  
2 Genderwise distribution  of  Post  Renal  Transplant patients  
3 Distribution  of  Post  Renal  Transplant patients  according to donors  
4 Distribution  of  Culture  positivity   according  to  gender    
5 Distribution  Of Asymtomatic/symptomatic  Candiduria  among Post  Renal  Transplant  recipients  
6 Distribution of Candida  isolates from Post Renal Transplant recipients  
7 
Antifungal Susceptibility  Pattern of Candida  albicans  
isolates from urine samples of Post Renal Transplant 
recipients 
 
8 
Antifungal Susceptibility  Pattern of Candida  glabrata  
isolates from urine samples of Post Renal Transplant 
recipients 
 
9 
Antifungal Susceptibility  Pattern of Candida  krusei 
isolates from urine samples of Post Renal Transplant 
recipients 
 
10 
Antifungal Susceptibility  Pattern of Candida  tropicalis 
isolates from urine samples of Post Renal Transplant 
recipients 
 
11 Distribution  of Candida  parapsilosis  isolates from urine samples of Post Renal Transplant recipients  
12 
Distribution of Biofilm producers and  Non biofilm 
producers among Candida  isolates from Post Renal 
Transplant recipients  
 
13 Antifungal resistance   Pattern  among  Candida   isolates from urine samples of Post Renal Transplant recipients  
 
  
LIST OF COLOUR PLATES 
 
 
Sl. 
No. TITLE 
1. Identification  of  Candida  albicans 
2. Identification  of  Candida   glabrata 
3. Identification  of  Candida   krusei 
4. Identification  of  Candida  parapsilosis 
5. Identification  of  Candida   tropicalis 
6. Minimum Inhibitory  concentration  by E-Strip  for Candida  krusei 
7. Biofilm   production  by  tube   method 
 
 
 
 
 
  
  
  
 CERTIFICATE II 
 
 This is to  certify  that this  dissertation work  titled   “ ISOLATION AND 
CHARACTERISATION OF CANDIDA SPECIES FROM POST- RENAL 
TRANSPLANT RECIPIENTS WITH URINARY TRACT INFECTION 
WITH SPECIAL REFERENCE TO ECHINOCANDINS” of the  candidate 
Dr.Arthy.G  with registration number 201614002 for the award of M.D.,Degree  
in the branch of Microbiology. I  personally verified  the urkund.com website   
for the purpose  of plagiarism  check. I found that  the uploaded thesis file  
contains from introduction to conclusion pages and result shows   0  percentage 
of plagiarism in the  dissertation. 
 
 
 
 
 
 
 
 
Guide & Supervisor sign with seal  
 
 
 
 
 
Introduction 
  
1 
 
 
 
 
INTRODUCTION 
 
 Infection   is  one  of   the  important  cause of  mortality  among renal  
transplant recipients(5). Urinary tract infection is the most common etiology 
accounts  for  45-72%  and  sepsis  for about  30%  among  kidney 
transplantation, because  of their immuno suppressed state,  these  renal 
transplant  recipients   are   prone  to  develop various fungal infections (24).  
Among the renal transplant  recipients ,Candida species  appears to be the 
most common organism  causing  UTI  (27). 
 
 Candida albicans  is the most cause  of UTI   among renal transplant  
recipients however candida non-albicans infections are increasing 
nowadays consisting of 35-65% (28). 
 
 Considering the difference in susceptibilities to antifungals among 
candida identification to the species level has a major role in treatment of 
candidiasis(29). 
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 The emergence of Azole resistant candida species is a cause for 
concern. Therefore a need for newer antifungal drugs which will eradicate 
Azole resistant candida species has led to the consideration of 
Echinocandins. 
 
 This  study  is  mainly   to  assess the efficacy of Echinocandins for 
their antifungal  activity  against  Azole  resistant  Candida  species 
  
Aims & Objectives 
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AIM & OBJECTIVES 
 
AIM : 
 To isolate and characterize Candida species from the urine samples of 
post renal transplant recipients from Urology and Nephrology wards. 
 
OBJECTIVE: 
1. To isolate and characterize Candida species from urine samples of 
post – renal transplant recipients from Urology and Nephrology 
wards. 
2. To Perform antifungal susceptibility pattern for isolated Candida 
species. 
3. To analyze the efficacy of Echinocandins on Azoles resistance 
candida isolates by using E-test. 
4. To detect Biofilm production in Candida isolates from Urine samples 
in post renal transplant recipients. 
  
Review of Literature 
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REVIEW OF LITERATURE 
 
The fungal kingdom 
 
 Fungi are diverse microorganisms in nature .The fungal kingdom 
consists of yeasts and filamentous eukaryotic organisms, and is divided into 
8 phyla comprising the Chytridiomycota, Zygomycota, Ascomycota, 
Basiodiomycota,Urediomycota,Ustilaginomycota,GlomeromycotaandMicro
sporidia. Fungi are saprophytic and live on dead or decaying organic matter. 
The cell wall of these eukaryotic fungi is rigid and mainly made up of N-
acetylgiucosamine (chitin), complex polymers of glucose (β 1, 3 and β 1, 6-
glucan) and cell wall mannoproteins. Their mode of reproduction is either 
by budding off cells or by dissemination of spores.  
 
 Fungi have a great influence on humans in both beneficial and 
harmful ways. Fungi play an essential role in maintaining the ecosystem by 
breaking down organic materials and there by releasing energy and minerals 
back into the environment. Some fungi are the source of drugs including 
Penicillin, Cephalosporin and other antibiotics.  
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Members of Ascomycota are biologically diverse and contain the most 
pathogenic fungi that cause life-threatening infections in the human host, 
although a few pathogenic fungi are members of Basidiomycota or 
Zygomycota. The class Eumycota includes genera such as Saccharomyces, 
Pichia, Endomycopsis, Nematospora, and Candida whereas the genus 
Cryptococcus belongs to the class Basidiomycota. Candida and 
Cryptococcus are the most frequent genera implicated in human infections 
and about 60 − 70% of patients admitted into Intensive Care Units (ICUs) 
have symptoms caused by Candidaspecies. Other fungal pathogens 
implicated    in   human   infections  include 
Trichosporon,Fusarium,Histoplasma,Penicillium,Coccidioides,Rhizomucor,
TrichophytonandAspergillusspecies 
 
 The single most common genus to cause opportunistic fungal 
infection among immunocompromised hosts  is Candida, although the list 
of opportunistic fungi causing life-threatening infections among the 
immunocompromised increases periodically. 
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 Yeast are  the significant part   of  normal  flora of human beings. 
They  are   mainly found on skin,mucous membrane, genital  tract. Most  
yeast are oppurnistic in nature  as  they lack  ability  to penetrate skin which  
is  the major property  of  pathogen .At present  there are 163  anamorphic  
species  of  genus Candida and   thirteen  genera of  teleomorphs . 
Other  candida  species; 
a. Candida kefyr 
b. Candida guilliermondii 
c. Candida glabrata 
d. Candida krusei 
e. Candida  tropicalis 
f. Candida auris 
g. Candida rugosa 
h. Candida lusitaniae 
i. Candida viswanathii 
j. Candida haemulonii 
k. Candida parapsilosis 
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CLINICAL CLASSIFICATION OF  CANDIDIASIS: 
I.INFECTIOUS DISEASES: 
A. Mucocuatneous manifestations: 
oral :thrush,stomatitis,glossitis,chelitis 
Alimenatary :Esophagitis,Gastritis. 
vaginitis ,balanitis,balanoposthitis 
Chronic mucocutaneous Candidiasis 
Ocular Candidiasis 
B.Cutaneous Manifestations: 
Intertriginous and Generalized 
Paronychia and onychomycosis 
Diaper dermatitis 
Candidal granuloma 
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C.Systemic manifestations: 
Urinary tract infection 
Endocarditis 
Pulmonary candidiasis 
Meningitis 
Candidemia 
Arthritis 
Osteomyelitis 
Endophthalmitis 
II.ALLERGIC DISEASES: 
Candidids 
Eczema 
Asthma 
Gastritis 
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PATHOGENESIS: 
Adherence to epithelial and  endothelial  cells. 
Enzymes production: proteinase and Phospholipase. 
Pseudohyphae production. 
Hyphae transformation occurs  during  an  active  infection.. 
 Cell surface hydrophobicity which increases  the ability of mycelial 
phase  of Candidal cells to adhere to host tissues  and become  
resistant to phagocytic killing. 
Immunity : 
 Classical  T cell  mediated  immunity  plays  a vital  role  candidal  
colonization. IL-3 plays  a  major  role  followed  by GM-CSF,M-CSF  and  
G-CSF. 
CANDIDA ANTIGENS: 
CELL WALL ANTIGENS 
 Mannan  is  the  major  antigenic  component  of Candida  cell wall  
,which  contributes main virulence  of the  candida.  Glucan  polymers 
which are   greater  than  mannansbut immunologically less  active. 
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CYTOPLASMIC  ANTIGENS: 
SEROLOGICAL TEST FOR INVASIVE CANDIDIASIS: 
 A.DETECTION  OF ANTIBODIES:  
Slide agglutination  
Immunodiffusion 
Phytohemagglutination 
Coelectrophoresis 
Immunoprecipitation 
A and B immunofluorescence 
 B.NON SPECIFIC CANDIDA ANTIGENS: 
 Latex agglutination 
Immunodiffusion 
 C.CELL  WALL  COMPONENTS: 
Cell wall  Mannoprotein (CWMP) 
Β – (1,3)-D- glucan 
 D.CANDIDAENOLASE  ANTIGEN TESTING   
11 
 
 
 
 DETECTION OF METABOLITES:  
 Candida produces the  metabolite  D- mannose and D- arabinitol  
which   is measured  by  Gas  liquid Chromatography. 
 G-TEST : 
 Mainly  for  the  detection of Glucan in candida. 
 PNA FISH 
 Peptide nucleic  acid  fluorescent  in situ hybridization (PNA FISH) 
method  is useful  for the  identification  of  candida  species. 
 
 T2 CANDIDA  PANEL 
Candida albicans 
Candida tropicalis 
Candida parapsilosis 
Candida krusei 
Candida glabrata 
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CANDIDA  SCORE : 
1. Multiple  colonization( 1 point) 
2. Surgery  upon  ICU admission ( 1 point) 
3. Total parenteral nutrition ( 1 point) 
4. Severe sepsis ( 2 point) 
Score   >2.5  indicates increased  likelihood  of  invasive  candidiasis. 
 
Renal Transplantation: 
 First recorded human kidney transplant was conducted in the year 
1906 by Jaboulay. First renal transplantation was conducted by Joseph 
Murray and his colleagues between twin brothers. Then Murray was 
awarded Nobel Prize in Medicine field  for  his  great contribution  in Renal 
transplantation which appears to be an important among CKD patients(12). 
 
Harvested Kidney Placement: 
 Renal transplantation is done by placing kidney in the recipient iliac 
fossa, better in opposite iliac fossa to place renal pelvis and proximal ureter 
medial and superficial to renal vessels which is the ideal position . This is 
done  to   prevent   vascular injury during subsequent repair of an obstructed 
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renal  transplant ureter which can   occur  commonly. Urinary bladder 
retains to its normal function within 6 months of post transplantation (55). 
 
Transplantation prognosis depends on immunological and non 
immunological factors like; 
a. Biological 
b. Immune 
c. Genetic 
d. Metabolic 
e. Pharmacologic factors 
f. Time on dialysis 
g. Donor and kidney characteristics 
 
 Renal transplantation is the treatment of choice  for ESRD excluding 
patients with active infection and malignancy, peri operative morality, 
altered anatomy etc.(3). 
  
Non transplant Kidney replacement therapy (2) 
Non transplant of kidney replacement therapy include; 
a. Hemodialysis 
b. Peritoneal dialysis 
Hemodialysis – uses machine and artificial kidney membrane. 
Peritoneal dialysis – peritoneal membrane 
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Hemodialysis: 
Hemodialysis  filtration 
Continuous veno venous hemofiltration 
Continousveno venous hemodialysis 
 
Peritoneal dialysis 
 Continuous ambulatory peritoneal dialysis 
 Continuous cyclic peritoneal dialysis 
 
Role of immune suppressive therapy in renal transplant 
 Renal transplantation is   the  treatment of choice for ESRD. Our 
body’s immune responses has three phases a recognition of Foreign antigen. 
Antigen specific lymphocytes activation and effector phase. The above 
response leads to loss of the transplant in recipient if not brought under 
control. 
 
 This leads to the   use  of immunosuppressive agents in 
transplantation (4,1). 
 
Immunosuppressive therapy: 
Azathioprine: 
 Antimetabolite and prodrug of 6 mercaptopurine. It binds to DNA 
chains and inhibit DNA and RNA synthesis thereby prevent gene replication 
and T cell activation (56). 
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Tacrolimus: 
 Forms a complex with tacrolimus binding protein which binds with 
calcineurin and inhibits action of cytokines (IL-4, IL-2, IFN-, TNF-α) 
genes which causes T cell activation. 
 
Cyclosporine: 
 Binds with intracellular protein cyclophilin to form a complex which 
binds and inhibits calcieurin action. Main adverse effect of cyclosporine is 
Nephrotoxicity. 
 
Mycophenolatemofetil 
 It is an antimetabolite and reversible inhibitor of Inosine 
monophosphate – dehydrogenase which decreases guanosine nucleotide 
activity and thereby inhibits proliferative effect on lymphocytes. 
 
Corticosteroids 
 Inhibits expression of various cytokines IL – 6,2,3 TNF-α and 
Interferon gamma. It also has an anti-inflammatory action. 
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Sirolimus and Everolimus 
 Mammalian target of rapamycin (Mtor) – Regulatory kinase and 
causes inhibition of cytokine dependent cellular division of hematopoietic 
and non-hematopoietic cells. 
 
IL-2 receptor antagonist 
 Basiliximab and Daclizumab binds to IL-2 and inhibits its activity. 
 
Graft loss are highest within first few months after transplant. This 
necessitates importance of immunosuppressive agents during initial phase 
and later dosage reduction can be done. 
 
Rubin’s classification of post renal transplantation infection:  
 
a) Phase I (0 to 4 weeks after transplantation) 
1. First type : Infections present in the recipient prior to transplantation 
and has emerged as result of surgery, anaesthesia and vascular 
infections. 
2. Second type : Donor derived which is nosocomially acquired from 
systemic infection in donor or contamination during procedure – 
Staphylococcus aureus or candida species. 
3. Third type : complex surgical procedure which includes surgical site 
infections, bacteremia, pneumonia because of aspiration. 
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Nosocomial infections caused by antimicrobial resistant bacteria and 
candida species (4,1) 
 
Phase 2 (1 to 6 months after transplantation): 
a. Due to first phase infections – was inadequately treated. 
b. Viral Infections: 
Cytomegalovirus, Herpes Simplex virus, Shingles, Human herpes 
virus 6 or 7, Hepatitis B and C, Human Immunodeficiency virus, BK 
polyoma virus . 
c. Opportunistic infections: 
o Pneumocystis jiroveci 
o Listeria monocytogenes 
o Toxoplasma gondii 
o Nocardia 
o Aspergillus 
 
Phase3  (6 to 12 months after transplantation) 
a. First group (70-80%) - general population acquiring infection and 
community acquired respiratory virus. 
b.  Second group (10%) –End organ damage or malignancy  is  mainly  
due  to chronic viral infections 
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c. Third group (10%) – Patients with unsatisfied graft function requires 
immunosuppressive therapy and susceptible to infections by 
Bartonella, Rhodococous, Cryptosporidium, Microsporidia, 
Aspergillus, Zygomycetes and dematiaceous molds. 
 
Urinary tract infections in post renal transplantation recipients: 
Anatomy of urinary tract: 
 The urinary tract  comprises of kidneys,   ureters, bladder and urethra. 
Main function of kidneys is excretion of waste products, maintenance of 
water and electrolyte balance of body. 
 
 Bilateral organs present in retroperitoneum. The ureter measures 
about 25cm long. 
 
 The urinary bladder situated in pelvis it has capacity of 500ml. 
Bladder has an apex, base, superior, inferolateral surfaces. 
 
 The urethra in males longer than females. Three parts of urethra 
prostatic, membraneous, penile. 
 
 Length of male urethra – 20cm whereas in females – 4 cm long. 
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Table 1 : Urinary tract infections : definition and diagnostic 
criteria(22,23) 
Category Description Clinical Features Laboratory Investigation 
1 
Acute complicated 
Lower UTI, Cystitis 
(women) 
Dysuria 
Frequency 
Urgency 
>10WBC/mn 
>103 CFU/ml 
2 
Acute uncomplicated 
upper UTI, 
Pyelonephritis 
Fever, flank pain, no 
urologic abnormally 
>10WBC/mn 
>104 CFU/ml 
3 Complicated UTI Any combination of 
symptoms from 1 and 2 
plus atleast one 
complicating factor 
 
a. Operative or 
radiotherapeutic 
changes of urinary 
tract 
b. Immunodeficiency 
 
 Ureter stent / bladder 
catheter 
 Intermittent self 
catheterization 
 Diabetes mellitus 
 Residual volume 
 >100ml neurogenic 
bladder 
>10WBC/mn 
>105 CFU/ml women 
>104 CFU/ml in men 
4 Asymptomatic bacteriuria No urinary symptoms 
>10WBC/mm3 
>105 CFU/ml in two 
consecutive MSU 
cultures 
 
>24 h a part in 
women / single MSU 
culture in men 
5 Recurrent UTI uncomplicated 
Only female 3 episodes 
of uncomplicated UTI / 
1 year, absence of  
structural or functional 
pathology 
>103 CFU/ml 
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Symptomatic urinary tract infections 
 Urinary tract infection presents with dysuria, suprapubic pain, 
urgency and urinary frequency. Non specific symptoms fever, malaise also 
present (5). 
 
Complicated UTI 
 Associated with structural and functional abnormalities of urinary 
tract or acquiring on infection due to disease present earlier or failed 
therapy. 
 
Recurrent UTI 
 Symptomatic UTIs at a frequency of 3 or increased episodes over 
period of 12 months or 2 episodes in previous 6 months. 
 
Relapse UTI 
 Recurrence of urinary tract infection by same organism following 
treatment modality. 
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Table 2: Classification of urinary tract infection 
Infection at 
Anatomical 
level  
Grade of 
Severity Risk Factors 
Pathogens 
species 
susceptibility 
grade 
UR – Urethritis 
CY – Cystitis 
PN – 
Pyelonephritis 
US – Urosepsis 
1 : Low, cystitis 
2 : PN, Moderate 
3 : PN, Severe 
4 : US : Systemic 
Inflammatory 
response 
syndrome 
5 : US organ 
dysfunction 
6 : US organ 
failure 
O : No risk  
R : Recurrent 
 UTI 
E : Extra 
 urogenital 
 RF 
N : Nephropathic
 RF 
U :  Urologic RF 
C : Catheter RF  
a. Susceptible 
b. Reduced 
susceptibility 
c. Multidrug 
resistant 
 
Risk Factors: 
a. Elderly age group 
b. Duration of Hospitalization 
c. Prior reflux kidney disease 
d. Diabetes mellitus 
e. Bladder catheterisation – duration. 
f. Azathioprine causes bone marrow suppression associated with UTI. 
g. urinary tract  instrumentation  procedures 
h. Duration of stent placement 
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Among, Post renal transplant recipients UTI were found to be more 
common in patients who received (70%) as compared to live grafts(8). 
 
Pathogens causing UTIs in post renal transplantation recipients: 
 UTI in post renal transplant recipients caused by various organisms. 
Escherichia coli commonest gram negative bacteria followed by 
Enterococci, Pseudomonas species and staphylococcus species (9). 
 
Candida species are the most common fungal cause of UTI   among  
renal transplant recipients in which candiduria occurs in 11% and it is 
asymptomatic. 
 
 No diagnostic test distinguish infection from colonization in patients 
with asymptomatic candiduria. 
 
 No studies revealed  importance of pyuria or  semi quantitative 
cultures for UTI due to candida (5). 
 
 
Pathophysiology in UTI: 
Environmental factors 
 In women, vaginal introitus and periurethral area colonized with 
intestinal pathogens remains vital step in pathogenesis of UTI. 
23 
 
 
 
 Estrogen deficiency plays an important role in causing UTI among 
post menopausal women. 
 
 Vesicouretral reflux tends to accentuate UTI by maintaining residual 
urine in bladder. (13,14) 
 
Host factors: 
 Urine is good culture for bacterial growth. But it has antibacterial 
action such as extremes of osmolality, increased urea concentration and 
decreased pH known to inhibit bacterial growth. 
 
 TLR-4 has  an tremendous  role in preventing UTI. (15) 
 
Microbial Factors (31) 
a. Adhesin: 
 Binding of candida to epithelial and endothelial cells is controlled by 
adhesion of surface of fungus that interact with receptors of host cells. 
 
b. Enzymes: 
 Proteases 
 Lipases 
 Phospholipases 
 Esterases 
 Phosphatases 
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c. Toxins: 
 Extracts of cell wallswill have  Glycoprotein which are usually toxic 
and pyrogenic and induce anaphylactic shock. 
 
d. Complement receptors: 
 Candida albicans ability to bind and complement derived opsonins. 
 
e. Phenotypic switching : 
 Ability of an organisms of a particular strain to switch reversibility at 
the very high frequencies among the different colony phenotypes. Due to 
this  characteristics  it can grow in various  morphological forms from 
unicellular yeast to filamentous pseudohyphae and even true hyphae. 
 
 This switching enable adaptation to different conditions in host and 
helps fungus in evading host defense system. 
 
Clinical manifestations of UTI: 
Upper Urinary Tract Infection 
a. Fever with or without chills 
b. Flank Pain (14,15) 
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Lower UTI: 
 Suprapubic discomfort or pain 
 Painful micturition 
 Fever – usually absent 
 
Indwelling catheter patients – Flank pain and fever present in lower urinary 
tract infection (14,15). 
 
Diagnosis of urinary tract infection  
Specimen Collection: 
 Specimen collection has to be done with proper care as urine culture 
aids in diagnosis. Clean catch mid stream urine has to be collected in wide 
mouthed screw capped container after cleaning perineum / glans with 
antiseptic wipes (16). 
 
 
Specimen Transport: 
Presumptive diagnosis of UTI is done by; 
a. Macroscopic 
b. Microscopy 
c. Gram stain of uncentrifuged urine sample. 
 
Macroscopic appearance of urine samples; 
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 Freshly voided normal urine is clear and pale yellow in appearance. 
a. Cloudy Urine Bacterial Urinary Infection 
b. Red / Cloudy Urine Urinary schistosomiasis / bacterial infection 
c. Brown / Cloudy Urine Malaria 
d. Yellow – Brown  Green – Brown Obstructive Jaundice 
e. Yellow orange Hemolysis / Hepatocellular jaundice 
f. Milky White Bancroftianfilariasis 
 
Specimen transport: 
 Urine must be transported immediately to the lab within two hours of 
collection. If there  is a delay in transporting urine, boric acid (0.1g / 10ml 
of urine) used as preservative. 
 
 Urine must not be preserved with bactericidal chemical such as 
thymol, bleach, hydrochloric acid, acetic acid or chloroform. 
 
Microscopic examination of urine example: 
 Wet film examination of urine sample detects: 
a. Pyuria 
b. Red blood cell 
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c. Urinary cast 
d. Epithelial cells 
e. Yeast cells 
f. Motile trophozoites of Trichomonasvaginalis 
g. Eggs of Schistosomahematobium 
 
 Presence of 10 leukocytes/mm3 or 1 leukocyte / 7 HPF of 
uncentrifuged midstream urine sample suggests – pyuria. 
 
 Gram staining of smear from urine sample showing gram positive 
budding yeast cell with or without pseudohyphae. 
RANT – SHEPHERD METHOD… 
Starting with greatest dilution, pipette 1ml of each dilutions into 9 cm 
petri dishes. 
Then pour into each dish 10ml of Nutrient agar, melted & cooled to 
45 -50⁰C 
Mix for 10sec by moving  rapidly in different directions without 
spilling contents 
Allow agar to set then incubate at 37⁰C for 2 days. 
Count the colonies in the plates that were seeded with dilutions 
between 50 & 500 colonies/plate. 
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Starting with greatest dilution, pipette 1ml of each dilutions into 9 cm 
petri dishes. 
Then pour into each dish 10ml of Nutrient agar, melted & cooled to 
45 -50⁰C 
Mix for 10sec by moving  rapidly in different directions without 
spilling contents 
Allow agar to set then incubate at 37⁰C for 2 days. 
Count the colonies in the plates that were seeded with dilutions 
between 50 & 500 colonies/plate. 
 
Culture of urine samples 
Urine culture – performed by a semiquantitative. 
a. Quantitative 
b. Automated 
 
SEMIQUANTITATIVE METHOD: 
Standard Loop Method: 
 Calibrated loop that delivers 0.01ml of urine is recommended to 
detect lower number of organisms. 
 
 Media used cysteine lactose electrolyte deficient. 
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 Inoculated plates are incubated for 24 hours at 35⁰C to 37⁰C 
aerobically colonies are counted. 
 Number of CFU  x 1000  (0.001ml Loop) 
 Number of CFU x 100   (0.01ml Loop) 
 
 If there is no growth plates are incubated for 24 hours. 
 
 
 
Filter Paper Method: 
 Standard 6mm wide strip of blotting paper or filter paper used. Bent 
into L shape with 12mm long foot and sterilized at 160⁰C for one 
hour. 
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 Whole of angulated end and foot is dipped in uncentrifuged urine 
sample and pressed on culture medium. 
 Remove the strip and discard in disinfectant. 
 Incubate it  for24 hours. 
 
Upto 50 colonies can be counted and heavier growths are designated as ; 
 Confluent   ++ 
 Semi confluent  + 
 
Dip slide method 
 Dip slide – small plastic tray which has culture medium and 
immersed in urine container. 
 Viable bacteria – estimated from number of colonies. 
 Reported as confluent or semiconfluent growth. 
 
A. QUANTITATIVE METHOD 
 It is surface viable count. 
 Inoculum is deposited as drops of 0.02ml 
 
 Each drop is allowed to fall from a height of 2.5cm on to medium, 
where it spreads over an area of 1.5-2cm diameter. 
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 These five  plates would receive about  1 drop of particular dilution in 
separate numbered sectors.  
 
 Finally, counts are usually made in drop which  showsmore number 
of colonies without confluence (>20). 
 
 The total of 5 counts for each dilution in 5 plates gives viable count / 
0.1 ml of dilution. 
 
    No. of colonies x dilution factor 
 CFU/Ml =  ------------------------------------------------------- 
           Volume of culture plate 
 
 
Pour plate method : 
 
 As a compromise between sampling & overcrowding errors, counts of 
pure culture should be made on plates inoculated  to yield between  
50 -500 colonies. 
 Prepare serial 10 fold dilution of bacterial suspension ensuring one 
dilution will contain between 50 & 500 colonies 
 9 ml Nutrient broth taken into each of several sterile test tubes. 
 Mix uniformly bacterial suspension & transfer 1ml into 1st tube of 
nutrient broth using sterile pipette. 
 With fresh sterile 1ml pipette, mix the first dilution & then transfer 
1ml into next tube of nutrient broth. 
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 Starting with greatest dilution, pipette 1ml of each dilutions into 9 cm 
petri dishes. 
 Then pour into each dish 10ml of NA, melted & cooled to 45 -50 c 
 Mix for 10sec by moving  rapidly in different directions without 
spilling contents 
 Allow agar to set then incubate at 37 c for 2 days. 
 Count the colonies in the plates that were seeded with dilutions 
between 50 & 500 colonies/plate. 
 
 
B. AUTOMATED SYSTEM 
Sidecar, Alfred 60 AST and HB & L – automated sytems for rapid urine 
culture. 
Light scattering – Technology based. 
Monitor bacterial replication activity and provide real time growth curve. 
Strong positive samples get flagged. 
 They  offer  a large output  with minimal labor & a rapid turn around 
time compared with conventional methods. 
 Advantages may be offset by  substantial  cost of instrumentation  
these costs can be   justified only in laboratories that receive many 
specimens. 
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 Automated or semi-automated urine screening systems are 
commercially available, such as IRIS International, Inc., Chatsworth. 
 The instrument analyzes both the microscopic components &  urine 
chemistries by combining technology of both types of analyzers into 
one automated system.  
 
Treatment of UTI: 
Asymptomatic bacteriuria: 
 No consenses on management. 
Repeat culture with recommended technique. 
 1-3 months  – treated 5-7 months 
 >3 months  – Avoid treatment 
    Unless creatinine rise 
 
 No need for empiric treatment (17). 
 
 
Symptomatic UTI: 
Empirical oral /Parenteral therapy : 
Mild :  
  Ciprofloxacin  along  with  Amoxcillin 
 
  
34 
 
 
 
Moderately Severe: 
 Ciprofloxacin or ceftriaxone or Ampicillin sulbactam. 
 
Severe: 
 Empirical treatment: Piperacillin – Tazobactam or cefepime 
 Once culture susceptibility results available complete  these14 days of 
treatment with narrow spectrum antibiotic (17). 
 
Recurrent symptomatic UTI: 
 Imaging must be  done to rule out anatomical structural causes or 
persistent focus of infection. (17) 
 Candiduria 
 Asymptomatic– avoid treatment unless patient is neutropenic. 
 Symptomatic – fluconazole – 7 to 14 days. 
 Imaging of kidneys and collecting system to assess fungal mass (17). 
Prevention of UTI: 
 Prevention of UTI should be given priority as it plays major role in 
graft survival (5). 
 
Neurogenic Bladder and structural abnormalities of urinary tract 
should be corrected earlier.(18) 
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 Patient’s education on basic personal hygienic measures such as 
frequent voiding and proper hydration, prevents UTI among post renal 
transplant recipient.(5) 
 
Antifungal prophylaxis: 
 Fluconazole prophylaxis (400mg/day) reduce the incidence of 
candida infections (36). Itraconazde (2.5mg/kg) twice daily preventing 
candida infection. (35) 
 
 Amphotericin B used for preventing invasive fungal infections (37). 
 
Antifungal drugs: 
a) Nystatin: 
 Nystatin polyene antifungal acts against molds and yeast infections, 
commonly candida. Relatively non-toxic but has adverse effects like 
vomiting, nausea and diarrhea. It is inferior in preventing Invasive Fungal 
Infections (30,31) 
 
Azoles: 
Mechanism of action: 
 Inhibition of cytochrome P450 dependent C14 demethylation (sterol 
14α demethylas enzyme) in synthesis of ergosterol present in cell membrane 
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(31). Patients have asymptomatic elevation of hepatic enzymes within 2 
weeks after initiation of therapy (32). 
 
Voriconazole: 
 Voriconazole shows good invitro activity, towards all candida 
species, including Fluconazole resistant candida species (32). 
 
 Advantage of azoles over amphotericin B is their toxicity. 
Coadministration of voriconozde with calcineurin inhibitors is an 
alternative, dose reduction of immunosuppressive drugs required (33). 
 
Fluconazole: 
           Antifungal drug used  fortreating both  superficial and systemic 
fungal infections. Most commonly preferred antifungal as prophylactic 
agent (34). 
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Itraconazole: 
 Active against both yeast and molds, can be given in 
immunocompromised patients. Very effective in treating candidiasis. 
Itraconazole had lesser adverse effects and renal  damage(35). 
 
Ketoconazole: 
  Drug of choice for various clinical indications like chronic 
mucocutaneous candidiasis, blastomycosis, histopasmosis, 
coccidioidomycosis(31). 
 Imidazoles: 
 Miconazole   
 Bifonazole 
 Butoconazole 
 Clotrimazole  
 Econazole  
 Fenticonazole 
 Isoconazole   
 Oxiconazole 
 Sertaconazole   
 Sulconazole 
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Echinocandins: 
Mechanism of action: 
 The Echinocandins act as non-competitive inhibitors of B(1-3) D 
glucan synthase, present in fungal cell wall, organism cannot synthesize 
B(1-3)-D glucan leads to osmotic instability and cell death. 
 
 Echinocandins exhibit good fungicial activity against candida 
albicans, candida parapsilosis and candida guilliermondi & Echinocandins 
are also active against Amphotericin B – resistant and Fluconozole resistant 
candida glabrata(50-52). 
 Echinocandins preferred for candida species which shows reduced  
susceptibility to fluconazole (57-61). 
 
◦ Anidulafungin 
◦ Caspofungin 
◦ Micafungin 
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Biofilm: 
 It  is an association  of  micro-organisms in which  the   microbial 
cells  attach  to  each   other   on a   living  and non living  surfaces  within  
a  self producedmatrix of extracellular   polymeric  substance.(68) 
 
History : 
 In 17th century Anton  van  Leeuwenhoek   observed animalcule  on  
surfaces of  tooth   by using  a  simple  microscope  . The term Biofilm was  
coined by  Bill costerton in  1978. 
 
Biofilm  chemical  composition : 
 Microbial cells -   2 to 5 % 
 DNA & RNA  -  < 1 to 2  % 
 Polysaccharides  -   1-2% 
 Proteins - < 1-2 % 
 Water- upto 97% 
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Steps  involved  in  Biofilm  formation: 
1. Attachment  to  a  surface  initially 
2. Formation  of  Microcolony 
3. Three dimensional  structure  formation 
4. Biofilm formation , maturation, and detachment. 
 
Phenotypic Determination of Biofilm Formation  (67) 
Congo Red Agar Method (CRA)  
 This  medium  consists of  Brain Heart infusion, glucose , agar  and 
congo red stain. Congo red prepared as  aqueous solutionseperately and it 
has  to be autoclaved for 15mins at 121°C, and then congo red added when 
the agar had cooled to 55°C .Plates were  incubated aerobic condition at 
37°C for  24 to 48 hours. Positive result indicates dark red colonies.  
 
Tube Method (TM) : 
 A calibrated loopful of  organisms from the Sabouraud Dextrose Agar 
plate was inoculated onto tube containing 10ml of Sabouraud Dextrose 
broth which  was supplemented with glucose. These tubes were incubated at 
35°C for 24 to  48hours routinely. After incubation Period , the broth in the 
tube  was aspirated gently and thoroughly washed with distilled water . 
Then the tubes  will be stained with  primary stain( 0.1% crystal violet)  .  
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Biofilm formation is indicated by a a visible film seen  in  the margins  and 
bottom of the tube. 
 
Results:  
1- Weak /none 
2- Moderate 
3- High /strong 
 
Microtiter Plate Method (MTP) : 
 Sterile, 96 well , flat bottomed microtitre plates  filled with 100 μl of   
the cell suspension .  Then these Plates were incubated  roughly for 72 hours 
at 37 ° celcius. Plates were stained with  primary  stain crystal violet (0.1% 
w/v)  and  remaining stain was  cleared  off  with  deionized  water and the  
plates were  dried.OD  of stained   Candida biofilm was  usually determined  
by  ELISA  reader of 492 nm at wavelength.  OD values is an  significant 
index of  Candida  which remains adhered  to  thesurface and forming 
biofilms. 
  
Materials & Methods 
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MATERIALS AND METHODS 
 
Ethical consideration 
 This study was conducted with the approval from the Institutional 
Ethics Committee at Rajiv Gandhi Government Hospital and Madras 
Medical College, Chennai – 3. Informed consent was obtained from all the 
patients who was included in this study. 
 
Place of Study: 
 The Institute of Microbiology, Madras Medical College in association 
with the Institute of Nephrology, Institute of Urology, Rajiv Gandhi 
Government General Hospital and Madras Medical College, Chennai. 
 
Study period: 
This study was conducted for one year from March 2017 to  February 2018 
 
Study type: 
 Cross Sectional Study 
 
Statistical analysis:  
  Statistical analyses were carried out using Statistical Packages for 
Social Sciences (SPSS). The proportional data of this cross sectional study 
were analyzed using Pearson’s Chi Square analysis test.  
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Sample Size: 
 100 post renal transplant recipients with urinary tract infection from 
Urology and Nephrology Wards. 
 
Inclusion Criteria: 
1. Patients aged more than 18 years. 
2. Post renal transplant recipients with UTI. 
Exclusion Criteria: 
1. Patients  below 18 years. 
2. Patients with other solid organ transplantation 
3. Malignancy 
 
Methodology: 
 All the patients was selected as per the inclusion criteria and patient 
details were entered in the proforma. 
 
Specimen Collection: 
Collection of Urine Sample: (40,43) 
 Under aseptic precautions, 10 to 20 ml of urine sample was collected 
in a  sterile dry, wide mouthed  leak proof, screw capped container after 
educating the patient about the proper collection of the  urine sample. 
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Instructions to be followed in female patients for sample collection: 
a. Wash the hands with soap and water and clean periurethral area well 
with a mild soap and wash well with water. 
b. Once cleansing was completed retract the labial folds, begin to void 
and discard few ml of urine and midstream urine sample was 
collected. 
 
Instructions to be followed in male patients for sample collection: 
a. Wash the hands with soap and water and clean glans with mild soap 
and wash well with water. 
b. After cleansing was completed retract foreskin, begin to void and 
discard few ml of urine and midstream urine sample was collected. 
 
Sample Processing (40) 
 Samples were collected  and transported immediately within two 
hours of collection after proper labeling done samples were refrigerated at 
4oC if there is delay. Allurine  samples collected were subjected to 
Macroscopic and Microscopic  examination. 
 
A) Macroscopic Examination 
 Colour of the urine sample – clear, red, brown, milky white, 
appearance – clear or turbid were observed. 
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B) Microscopic Examination  
i) Wet Film Examination: 
 Uncentrifuged urine samples gives accurate leucocytes count. 
 High power dry objective of microscope used to observe the wet film 
and HPF calculated from field diameter measured by slide micrometer. 
 Place urine sample on microscopic slide and coverslip is placed over it. 
> 1 leucocyte / 7 HPF = >104 leucocytes / ml of urine 
 
ii) Direct Gram Stain: 
 Gram staining of smear from urine sample reveals gram positive 
budding yeast cells with or without pseudohyphae. 
 
iii) Culture of urine sample: 
 Urine samples collected from post renal transplant recipients were 
processed culture, identification and antifungal susceptibility testing will be 
done. 
 
Semiquantitative Culture Technique 
 A calibrated loop (4 mm) delivers 0.01ml volume of urine usd. 
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 Inserted vertically into container and withdrawn vertically. Touched 
to the centre of plate and inoculum was spared on a line along diameter on 
plate. 
 
 Loop was drawn across entire plate crossing first inoculum streak 
several times perpendicular to first streak. Cysteine lactoseelectrolyte  
deficient media, agar. Suspected candida colonies are subjected to gram 
stain. 
 
 Gram stain showed gram positive budding yeast cells with or without 
pseudohyphae 
 
 Candida was further speciated based on Germ tube tests, Dalmau 
plate culture method, sugar fermentation and assimilation test. 
 
a) Germ tube test (38,39) 
 Colonies of yeast were emulsified in 0.5ml of human serum and 
incubated for 2 hours at 37oC. A drop of suspension placed on glass slide 
and cover slip placed over it and observed under 40x. 
 
Positive  :  Candida albicans / Candida dubliensis 
Negative : Candida non-albicans species 
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b) Cornmeal tween agar (38,39) 
 Isolated yeast colony from primary culture taken using straight wire 
and then inoculated onto cornmeal agar with tween 80 plate by making 2-3 
parallel lines, 3.5-4 cm long and 1-2 cm apart and cover with sterile 
coverslip and incubate at 25oC for 48 hours. Examined under low power and 
high power at margin of coverslip for the presence of hyphae, blastoconidia 
and chlamydospores. Morphology on cornmeal tween 80 agar. 
 
C.albicans: 
 Elongated pseudohyphal cells with large clusters of blastoconidia at 
junctures between cells, sessile intercalary and many terminal 
chlamydospores seen. 
 
Candida dubliensis: 
 Large thick walled terminal chlamydospores with bunch  of round 
blastoconidia usually at the septa  
 
 
Candida tropicalis: 
 Blastoconidia single or small groups along pseudohyphae. Fir tree 
appearance. 
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Candida  parapsilosis 
 Short, thin marked curved pseudohyphal cells develop into large giant 
pseudohyphal cells. 
 
Candida krusei 
 Presence of pseudophyae with elongated blastoconidia gives match 
stick appearance. 
 
Candida  kefyer 
 Pseudohyphae with elongated blastoconidia i.e. parallel gives log in 
stream appearance 
 
Candida glabrata 
 No pseudohyphae, small oval budding yeast cells single terminal 
budding. 
 
Candida lusitaniae 
 Occasional blastoconidia at septa with short distinctly curved 
pseudohyphae 
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Candida guilliermondii 
 True hyphae  are absent and  small groups of blastoconidia are 
present at septa with few short pseudohyphae. 
 
C. Candida Chrom Agar (31,42) 
 Candida species subcultured on sabouraud dextrose agar and streaked 
on chrom agar plate. Incubated for 48 hours at 37oC. 
 
Appearance on chrom agar 
Species Colour 
Candida albicans Green 
C. dublinensis Light Green 
C.tropicalis Steel blue 
C.parapsilosis White to pale pink colonies 
C.krusei Pink colonies 
C.kefyr Lavender 
C.guilliermondii Pink to purple 
C.glabrata Cream to pink colonies 
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d) Sugar Fermentation Test (31,39) 
 Candida species subcultured in sugar free media at 37oC for 48 hours. 
0.2ml suspension added to 2% sugar fermentation media having Andrade 
indicator. Incubate at 30oC for 2-3 days. Fermentation indicated by acid and 
gas production. Glucose, sucrose, maltose, lactose tested. 
 
Sugar Fermentation test: 
Species Glucose sucrose maltose Lactose 
C.albicans AG AG - - 
C. dublinensis AG AG AG - 
C.tropicalis AG AG AG - 
C.parapsilosis AG - - - 
C.krusei AG - - - 
C.kefyr AG - - - 
C.guilliermondii AG -  - 
C.glabrata AG AG - - 
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e) Sugar assimilation test (31,39) 
 The test organism was subcultured on nutrient agar slope transfer 2ml 
of yeast suspension into another sterile test tube containing 1.5ml of yeast 
nitrogen base. Add this to 13.5ml of molten and cooled (40-45C plain agar. 
Twirl and pour into sterile petri dish allow to set at room temperature. 
 
Carbohydrate discs were placed on the agar plate  and usually incubated at 
25oC for 48 hrs. Growth around the disc is  positive 
 
Sugar Assimilation Test: 
Species Xylose Melibiose Raffinose Lactose Sucrose 
C.albicans + - - + + 
C.tropicalis + - - + + 
C.parapsilosis + - + - - 
C.krusei + - + - - 
C.glabrata + - - - - 
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Antifungal susceptibility: 
i) Disk Diffusion Method (53) 
 Inoculum prepared by picking 5 distinct colonies and suspending 
them in 5ml of sterile normal saline. Vortex the suspension for 15 seconds 
to prepare uniform inoculum. Adjust the turbidity with McFarland standard 
to achieve a stuck of 1.5x106 cells /ml. within 15 minutes of preparation. 
Sterile cotton swab dipped into suspension and streaked onto the Mueller 
hinton agar supplemented with 2% glucose and 0.5μg/ml methylene blue at 
an angle of 60⁰. 
 
 Inoculum was allowed to dry and the disc were placed with 
centeresatleast 24 mm apart.  The control strain C.albicans ATCC 90028 
was also placed. 
 
Antifungal discs used were Fluconazole, Voriconazole, Itroconazole, 
Nystatin B, Ketoconazole. 
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Interpretative criteria for antifungal susceptibility: 
Antifungal 
drug Disc potency 
Zone diameter range 
R SDD S 
Fluconazole  25 ug <14mm 15-18 mm >19 mm 
Voriconazole 1 ug <13 mm 14-16 mm >17 mm 
Itraconazole 10 ug <13 mm 14-16 mm >17 mm 
 
 
Minimum Inhibitory concentration by E-test method : (54) 
 Using a fresh pure culture inoculate 3-4 yeast colonies in sterile 
normal saline with a sterile swab. 
 
 Adjust inoculum with 0.5Mc Farland standard opacity with a sterile 
swab make a lawn culure twice on a quality passed plate wait for 3 minutes.
  
 
 The E test strips must be brought to room temperature for 30min 
before application and with sterile forceps place the sterile strip on the 
culture on Incubate at 37oC for 24 hours . 
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Organism 
CASPOFUNGIN -Minimum Inhibitory 
Concentration(MIC) – (0.002 -32μg/ml) 
Sensitive Intermediate Resistant 
Candida albicans <0.25 0.5 >1.0 
Candida glabrata <0.12 0.25 >0.5 
Candida krusei <0.25 0.5 >1 
 
DETECTION OF  BIOFILM PRODUCTION: 
Tube Method (TM) : 
 A calibrated loopful of  organisms from the Sabouraud Dextrose Agar 
plate was inoculated into tube containing 10ml of Sabouraud Dextrose broth 
which  was supplemented with glucose. These tubes were incubated at 35°C 
for 24 to  48hours routinely. After incubation Period , the broth in the tube  
was aspirated gently andthoroughly washed with distilled water . Then the 
tubes  will be stained with  primary stain( 0.1% crystal violet)  .  Biofilm 
formation is indicated by  a visible film seen  in  the margins  and bottom of 
the tube. 
 
Results:  
1- Weak /none 
2- Moderate 
3- High /strong 
Results 
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RESULTS 
 
 This cross sectional study   was  conducted  for a period  of one  year 
from  March  2017  to  February  2018 at the  Institute Of Microbiology 
Madras Medical college in association with the  Institute of  Nephrology  
and  the Institute of Urology ,Rajiv Gandhi   Government General Hospital 
and Madras Medical College,Chennai-3. 
 
 A total  of 100 patients  underwent Renal transplantation  at 
RGGGHbetween  March  2017  to February 2018. 
 
Samples: 
 In this present study  about two  clean catch Midstream  urine samples  
were collected  from each   post renal transplant recipient on the 3 rd month 
(I visit) and one year (II visit). 
 
 Hence number  of samples processed were (i.e.100 patients x 2  
samples each ). 
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TABLE  7   :  AGE WISE  DISTRIBUTION  OF  POST  RENAL  
TRANSPLANT PATIENTS(n=100) 
 
Age group (in years) No.of patients Percent %  
20-30 Years 35 35 % 
31-40 Years 28 28% 
41-50 Years 26 26% 
51-60 Years 11 11% 
Total 100 100% 
 
 Majority  of patients  who underwent  renal   transplantation were in 
the age group  of 20-30  years. 
 
Figure 1 :AGE WISE  DISTRIBUTION  OF  POST  RENAL  
TRANSPLANT PATIENTS (n =100) 
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TABLE 8:    GENDER  WISE DISTRIBUTION  OF  POST  RENAL  
TRANSPLANT PATIENTS (n =100) 
Gender No.of patients Percent 
Male 67 67% 
Female 33 33% 
Total 100 100% 
 
Males  were  predominant who underwent  transplantation  were  from renal   
transplantation 
FIGURE 2:  GENDER  WISE DISTRIBUTION  OF  POST  RENAL  
TRANSPLANT PATIENTS (n =100) 
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TABLE  9:    DISRIBUTION  OF  POST  RENAL  TRANSPLANT   
PATIENTS  ACCORDING TO DONORS (n= 100) 
Live/deceased No.of Donors Percent 
Cadaver 53 53% 
Live 47 47% 
Total 100 100% 
 
Most of  the recipients who underwent  renal   transplantation   were from 
Deceased  donor 53(53%). 
FIGURE  3: DISRIBUTION  OF  POST  RENAL  TRANSPLANT   
PATIENTS  ACCORDING TO DONORS (n= 100) 
 
  
53%
47%
Deceased donor
Live donor
59 
 
 
 
 
TABLE : 10 (A)    DISTRIBUTION OF CULTURE  POSITIVITY IN  
URINE  SAMPLES  COLLECTED  DURING  THE  FOLLOW  UP  
VISITS  IN  POST  RENAL  TRANSPLANT  RECIPIENTS (n= 200). 
Culture Culture  
Positive No  Growth Total p value Visits 
Visit  I 21(10.5%) 79(39.5%) 100(50%) 0.006 
Visit  II 14(7%) 86(43%) 100(50%) 0.007 
Total 35(17.5%) 165(82.5%) 200(100%)  
p <0.005 statistically significant 
 
Majority of  culture  positivity  were  observed  during  first  visit  
21(10.5%). 
 
TABLE  10 (B): DISTRIBUTION  OF  CULTURE  POSITIVITY   
ACCORDING  TO  GENDER  (n= 35) 
 
 
Gender 
Total P value 
Males Females 
Visit  I 8 (22.9%) 13(37.1%) 21(60%) 0.047 
Visit II 3(8.6%) 11(31.4%) 14(40%) 0.001 
Total 11(31%) 24(69%) 35(100%)  
p <0.005 statistically significant 
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FIGURE  4 : DISTRIBUTION  OF  CULTURE  POSITIVITY   
ACCORDING  TO  GENDER  (n= 35) 
 
 
 
 
TABLE 11:DISTRIBUTION  OF ASYMTOMATIC/SYMPTOMATIC  
CANDIDURIA  AMONG POST  RENAL  TRANSPLANT  
RECIPIENTS (n= 100) 
Symptomatic / 
AsympomaticCandiduria No.of Isolates Percent 
Asymptomatic 79 79% 
symptomatic 21 21% 
Total 100 100% 
 
 
Most of the post  renal transplant recipients  had Asymptomatic candiduria 
79(79%).  
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FIGURE 5 :DISTRIBUTION  OF ASYMTOMATIC/SYMPTOMATIC  
CANDIDURIA  AMONG POST  RENAL  TRANSPLANT  
RECIPIENTS (n=100) 
 
 
 
TABLE 12 :DISTRIBUTION OF CANDIDA  ISOLATES FROM 
POST RENAL TRANSPLANT RECIPIENTS (n=35) 
 
Species I VISIT II VISIT Total  
Candida albicans 11(31.4%) 7(20%) 18(51.4) 
Candida glabrata 4(11.43%) 2(5.71) 6(17.1) 
Candida tropicalis 3(8.6%) 3(8.6%) 6(17.1%) 
Candida krusei 2(5.71) 1(2.9%) 3(8.7%) 
Candida 
parapsilosis 1(2.85) 1(2.9%) 2(5.7%) 
Total 21(59.9%) 14(40.1%) 35(100%) 
 
79%
21%
Asymptomatic
symptomatic
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Most  common candida isolated  from  urine samples were Candida 
albicans11(31.4%) followed by  candida glabrata 4(11.43%) among candida 
non- albicans. 
 
FIGURE : 6 DISTRIBUTION OF CANDIDA  ISOLATES FROM 
POST RENAL TRANSPLANT RECIPIENTS (n=35) 
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TABLE  13 : Antifungal Susceptibility  Pattern Of Candida  albicans  
Isolates From Urine Samples Of Post Renal Transplant 
Recipients(n=18) 
Anti fungal drugs Sensitive Resistant 
Fluconazole 
(25 ug) 13(72.1%) 5(27.7%) 
Itraconazole 
(10 ug) 11(61.1%) 7(38.9%) 
Voriconazole 
(1 ug) 13(72.1%) 5(27.8%) 
Nystatin B 
(1 ug) 15 (83.3%) 3(16.7%) 
 
Majority of candida  albicans isolated from post renal treansplant  recipients  
were sensitive to  Fluconazole  (72.1%) and Voriconazole (72.1%) 
FIGURE  7 : Antifungal Susceptibility  Pattern Of Candida  albicans  
Isolates From Urine Samples Of Post Renal Transplant 
Recipients(n=18) 
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TABLE 14:Antifungal Susceptibility  Pattern Of Candida  glabrata  
Isolates From Urine Samples Of Post Renal Transplant Recipients(n=6) 
Anti fungal drugs Sensitive Resistant 
Fluconazole 
(25 µg) 0 6(100%) 
Itraconazole 
(10 µg) 0 6(100%) 
Voriconazole 
(1 µg) 0 6(100%) 
Nystatin B 
(1 µg) 3(50%) 3(50%) 
 
Majority  ofCandida  glabrata  isolates  were  resistant to Fluconazole  
(100%) , Itraconazole (100%) and Voriconazole (100%) 
 
FIGURE  8 :Antifungal Susceptibility  Pattern Of Candida  glabrata  
Isolates From Urine Samples Of Post Renal Transplant Recipients(n=6) 
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TABLE :15Antifungal Susceptibility  Pattern Of Candida  krusei 
Isolates From Urine Samples Of Post Renal Transplant Recipients(n=3) 
Anti fungal drugs Sensitive Resistant 
Fluconazole 
(25 µg) 0 3(100%) 
Itraconazole 
(10 µg) 0 3(100%) 
Voriconazole 
(1 µg) 0 3(100%) 
Nystatin B 
(1 µg 2(67%) 1(33%) 
 
Majority  ofCandida  krusei isolates  were  resistant to Fluconazole  (100%) 
, Itraconazole (100%) and Voriconazole (100%) 
FIGURE  9 :Distribution  Of Candida  krusei Isolates From Urine 
Samples Of Post Renal Transplant Recipients(n=3) 
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TABLE  16:Antifungal Susceptibility  Pattern Of Candida  tropicalis  
Isolates From Urine Samples Of Post Renal Transplant Recipients(n=6) 
Anti fungal drugs Sensitive Resistant 
Fluconazole 
(25 µg) 2(100%) - 
Itraconazole 
(10 µg) 4(67%) 2(33%) 
Voriconazole 
(1 µg) 4(67%) 2(33%) 
Nystatin B 
(1 µg) 3(50%) 3(50%) 
 
Majority of Candida  tropicalis isolated from post renal transplant  
recipients  were sensitive to  Fluconazole  (100%) and Itraconazole (67%). 
 
FIGURE  10 :Distribution  Of Candida  tropicalis  Isolates From Urine 
Samples Of Post Renal Transplant Recipients(n=6) 
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TABLE :17Antifungal Susceptibility  Pattern Of Candida  parapsilosis 
Recipients(n=2) 
Anti fungal drugs Sensitive Resistant 
Fluconazole 
(25 µg) 2(100%) - 
Itraconazole 
(10 µg) 2(100%) - 
Voriconazole 
(1 µg) 1(50%) 1(50%) 
Nystatin B 
(1 µg) 2(100%) - 
 
Majority  of  Candida  parapsilosis isolates  were  sensitive  to Fluconazole  
(100%)  followed by  Itraconazole (100%) and Nystatin  B(100%) 
FIGURE   11  :Distribution  Of Candida  parapsilosis  Isolates From 
Urine Samples Of Post Renal Transplant Recipients(n=3) 
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TABLE :18 BIOFILM PRODUCERS AND  NON BIOFILM 
PRODUCERS AMONG CANDIDA  ISOLATES FROM POST RENAL 
TRANSPLANT RECIPIENTS (n=35) 
Species Biofilm Producers 
Non Biofilm 
Producers Total 
Candida albicans 10(28.6%) 8(22.9%) 18(51.5) 
Candida glabrata 3 (8.6%) 3(8.6%) 6(17.2) 
Candida 
tropicalis 5(14.3%) 1(2.9%) 6(17.1%) 
Candida krusei 2(5.71) 1(2.9%) 3(8.4%) 
Candida 
parapsilosis 1(2.9%) 1(2.9%) 2(5.8%) 
Total 21(60%) 14(40%) 35(100%) 
 
Majority of Biofilm produced by Candida  albicans 28.6% andCandida 
glabrata(8.6%) among  Candida  non –albicans 
FIGURE  12 :  DISTRIBUTION OF BIOFILM PRODUCERS AND  
NON BIOFILM PRODUCERS AMONG CANDIDA  ISOLATES 
FROM POST RENAL TRANSPLANT RECIPIENTS (n=35) 
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TABLE :19  ANTIFUNGAL RESISTANCE   PATTERN  AMONG  
CANDIDA   ISOLATES FROM SAMPLES OF POST RENAL 
TRANSPLANT RECIPIENTS(n =7) 
Species Fluconazole (n=2) 
Itraconazole 
(n=4) 
Voriconazole 
(n=1) 
Total 
(n=7) 
Candida 
krusei 2 (28.6%) 2 (28.6%) 2 (28.6%) 2 (28.6%) 
Candida 
glabrata 4(57.1%) 4(57.1%) 4(57.1%) 4(57.1%) 
Candida 
albicans 1(14.3%) 1(14.3%) 1(14.3%) 1(14.3%) 
Total 7(100%) 7(100%) 7(100%) 7(100%) 
 
FIGURE  13:   ANTIFUNGAL RESISTANCE   PATTERN  AMONG  
CANDIDA   ISOLATES FROM URINE SAMPLES OF POST RENAL 
TRANSPLANT RECIPIENTS(n=7) 
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DISCUSSION 
 
 Renal  transplantation   is considered  to  be the  most  standard  
treatment   in patients  with  End  stage  renal  disease (62). Even though  
recent   advances have been  made  in operational   procedures  and 
emerging  newer   immunosuppressive  drugs    in  renal  transplantatation   
Still infection remains   as a  major  hindrance. Urinary  tract  infections  
plays a foremost  role  among  all  the infections   occurring  in  post  renal  
transplant   period   which  interferes   with graft  function if  not  treated 
properly. 
 
 This  cross sectional  study  was conducted for a period  of one year 
from March 2017   to   February  2018  A total  of 100 patients who 
underwent  renal transplantation  at  Rajiv  Gandhi Government  General  
Hospital  between  March 2017   to   February  2018. 
 
 All the patients were  followed  up at 3 rd month (I Visit) and after  1 
year  (II Visit) in post renal transplant period to detect candiduria. Therefore   
a  total  of 200  samples were    processed   in this   study. 
 
 Among  100  patients  included  in the  present study  67 (67%) were  
males  and 33 (33%)  were  females (Table  :8). Most of the   patients  who  
underwent   renal  transplantation  fall  in the   age   group  of 31  to 40  
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years( Table :7).About 53 (53%)  of renal  transplant  recipients  received  
deceased  graft  compared to live donor  47(47%)(Table : 9). 
 
 Incidence of  culture  positivity  indicating UTI  among  200 urine   
samples  from  Post renal  transplant were  35 (17.5%) ( Table  10 (A)).Out 
of 35  culture  positives,21(10.5%) urine samples  showed  culture  
positivity  during their   I visit  i.e3 rd month  of post renal transplantation  
and 14 (7%)  showed  culture  positivity  during II   Visit(  one year after 
transplantation)(Table :10 (A)). 
 
 Hence  culture  positivity  was maximum  during  first visit when  
compared  to second visit , which was compared to the study by  
Alangader.G  at Detroit in 2007  and  Munoz.D at spain in 2000 shows UTI  
occur  at  any  time after  transplantation   highest  incidence  reported  in 
first  3- 6 months.(20) 
 
 Incidence of  UTI  among  Post  renal  transplant  recipient  was  
17.1% in this present study ,but  itseems  to be comparatively lesser  when  
compared  to other   studies  conducted  by  SeyyedeFatemah shams et al at 
Iran  from  2012  to 2014   and  M. V. N. L. R. Mohan et al at  South India  
in 2014 which were 22.7%( 64) and 41.9% (69)respectively. Most  probable 
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reason  could  be strict  aseptic precautions ,post-operative care  and  
immunosuppressive therapy etc. 
 The incidence  of  UTI  among  female  patients  was   26 % which is 
higher  than  males  16.5% and   this  is similar  to most of the studies done 
previously. 
 
 In  this   study  majority  of patients  in whom UTI  was diagnosed  
remains  asymptomatic 79(79%) when Compared to Symptomatic 
Candiduria21(21%).This would be because of impaired 
inflammatoryresponse  in   these  patients. 
 
 Among 35 candida isolates from   post renal transplant  recipients 
21(60%) isolated from recipients who received graft from deceased donor 
and 14 (40%) from live donor developed UTI   which was similar to the 
study of   Rivera –sanchez et al  were the patients  developed  UTI  From 
deceased donor  than live donor  which was only (28%).This may be due to 
septicemia  or some other  complications which have lead to death in these 
ill patients.However  ,further studies needed for this regard. 
 
 Among the candida isolates, Candida albicans 18 (51.4%) is the most 
common followed by Candida non – albicans 17 (48.6%) which is similar 
to the study conducted by M.R.Yazdani et al at   Iran  from 2009 to 2014(20). 
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 The distribution  of organisms in this study  causing candiduria 
among post renal transplant  recipients were Candida albicans11(31.4%), 
Candida glabrata11(43%), Candida tropicalis3(8.6%), Candida 
krusei2(5.7%)and  Candida  parapsilosis 1(2.85%) respectively. (Table 12). 
 
 The predominant  organisms among candida non albicans in both I 
and II visit is Candida glabrata 4 (11.43%)  and 3(8.6%) respectively which 
is  similar to the study conducted  by M.R.Yazdani et al at  Iran from  2009  
to 2014(20).Among the 18 Candida albicans isolates most of them were 
sensitive to Fluconazole 13(72.1%),Itraconazole 11 (61.1%),Voriconazole 
(72.1%), and Nystatin B 15 ( 83.3%). 
 
 Among the 6 Candida  glabrata isolates from post renal transplant 
recipientas were sensitive to Nystatin .Nonetheless all the isolates were 
resistant to Azoles which is similar to  study conducted by R.Deepa et al  in 
Mangalore  from 2012 to  2013 which shows intrinsic resistance of Candida 
glabrata against  Azoles(66,31). 
 
 Out of 3 Candida kruseiisolates  all were  resistant to Azoles  which  
necessitates  role  of  Echinocandins(31).Among 6 Candida tropicalisisolates 
majority of them were sensitive  to  azoles and Nystatin B. 
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        Out of 2 Candida parapsilosis  isolates most of  them were  sensitive  
to azoles  and Nystatin B. 
 Among 35 Candida isolates ,Biofilm  is predominantly produced by 
Candida albicans 10(28.6%),followed by  Candida glabrata 3(8.6%), 
Candida tropicalis 5(14.3%), Candida krusei 2(5.77%) and Candida 
parapsilosis1(2.9%)  which is consistent  with study conducted  by 
Hetalsida et al in Gujarat in 2015 showed Candida albicans 26(38.8%) as 
the predominant to  produce biofilm followed by Candida tropicalis 
1(1.49)(67). 
 
 Among  7  Candida  isolates which showed  azole resistance , 
Candidaglabrata  4(57.1%) ,Candida krusei  2(28.6%) and Candida 
albicans (1(14.3%).All the 7 isolates ofCandida albicans and Candida 
nonalbicanswere 100 % susceptible to Echinocandins (Caspofungin)which  
is analogous to  study conducted by R.Deepa  et al in Mangalore  from   
2012  to  2013 that Echinocandin had good invitro activity  against  Azole  
resistanceCandida isolates. 
 
  
Summary 
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SUMMARY 
 
 This   cross sectional  study   of    one  year   period  included  100 
patients who  underwent  renal  transplantation between  March 2017 
to February 2018. Two  CCMSU  Samples were  collected  from   
each  patient on 3rdmonth  (I visit) and  1 year  (II visit)  post 
transplantation    and   hence  200 urine   samples  were  processed. 
 The age   group   who  commonly underwent  renal  transplantation   
was  between  20  to  30  years. 
 Males  67(67%) were  predominant who  commonly    underwent  
renal  transplantation   . 
 The  incidence of UTI    among the   post renal   transplant recipients  
in  this  study  35(17.5%)  of  which the incidence of  UTI was  found   
to be  21(10.5%) ,14(7%)  during  the I  visit  and  II  visit 
respectively. 
 The  incidence of UTI    was  higher   in  females (24%)  and  males  
11%   in  this  present  study. 
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 Most of   the  Post Renal   Transplant recipients   had  Asympomatic 
Candiduria (79%). 
 Recipients  who  received   the  transplant  from  deceased  donor has  
a higher  propensity 21 (60%)  to acquire  UTI. 
 In  this  study  Candida albicans11(31.4%)  was the  most common  . 
 Among   the  35  Candida  isolates, most of  the isolates  are  
sensitive  to  Azoles and  Nystatin B  except  Candida glabrata  and  
Candida krusei  resistant to Azoles. 
 All  the  7  azole  resistant  Candida isolates  were  sensitive  to  
Echinocandins. 
 Among   the  35  Candida  isolates,  Biofilm  produced  
predominantly   by Candida albicans  followed  by  Candida  Non-
Albicans. 
 
  
Conclusion 
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CONCLUSION 
 Risk   of  infection  in  Post  Renal  transplant  recipients   mainly  by  
thestate of  Immunosuppression. 
 
 Females  were  identified  with  higher  incidence  of  UTI  so  proper 
personal  care   and  Education  should  be  advised. 
 
 Recipients  who  received   graft  from  deceased  donor  should  be  
followed  up  and  monitored as they  are  prone  for  developing   
UTI. 
 
 Proper  hydration ,frequent  voiding,  helps   in  preventing  UTI   
among  the  Post  Renal  Transplant  recipients    
 
 All patients   should  have  regular  follow  up with urine 
culture,followed  by  proper  antifungal usage. 
 
 Further, large  prospective long term  studies  are needed. 
 
 Role  of  Medical  microbiologist  is  crucial  to  help  physician  in   
diagnosing    the  UTI  and  make  them  aware   of  the     resistance  
pattern for  the  fungal  isolates. 
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Annexures 
 
 
APPENDIX- I 
ABBREVIATIONS 
 
CCMSU – Clean Catch mid stream urine 
CFU/ML –  Colony forming units 
CKD              – Chronic Kidney disease 
CLSI   – Clinical Laboratory Standard Institute 
DNA          – Deoxribonucleic acid 
E TEST – Epsilometer 
ESRD   – End stage renal disease 
HPF          –           High power field 
INF            _          Interferon  
IL        –          Interleukin 
MIC  –         Minimum inhibitory  concentration 
SDA –                 Sabouraud dextrose agar 
TLR –         Toll like receptor 
TNF    –         Tumor necrosis  factor 
UTI         _         Urinary tract infection 
  
APPENDIX II 
 
A).STAINS AND REAGENTS 
 
Gram staining: 
 Methyl violet(2%)-10g of Methyl violet in 100 ml Absolute alcohol in 1 litre of 
Distilled      water.(primary stain) 
 Grams Iodine-10g Iodine in 20 g KI (fixative) 
 Acetone-Decolourizing agent. 
 Carbolfuchsin(1%)-Secondary stain. 
 
B.MEDIA USED 
 
1.SABOURAUD DEXTROSE  AGAR  WITH  ANTIBIOTICS: 
 
INGREDIENT          Gm/ltr 
Peptone             10 gms 
Dextrose            40 gms 
Agar                  20 gms 
Distilled water    1000 gms 
Gentamicin           20 mg 
Final pH was  adjusted to   5.6 
 
 The  above ingredients  were  reconstituted in  one  litre  of   distilled  
water.Dissolve  the powder  water  by  boiling. Gentamicin  is added  to  the  boiling  
medium.The  medium  was then  removed  from  heating ,mixed  well and then  
dispersed  in  tubes  and  autoclaved  at  121deg celcius for  15  minutes   and the  final  
pH was   adjusted  to  5.6.The  tubes  were  cooled  in  slanted   position  and  later   the  
slants  were  stored in  refrigerator.   
 
2.YEAST  NITROGEN BASE  MEDIUM (DEHYRATED  MEDIA): 
INGREDIENTS GMS/L INGREDIENTS GMS/L 
Ammonium sulphate 5.000 Niacin 0.0004 
L-Histidine hydrochloride 0.010 p-Amino benzoic acid (PABA) 0.0002 
DL-Methionine 0.020 Pyridoxine hydrochloride 0.0004 
DL-Tryptophan 0.020 Riboflavin (Vitamin B2) 0.0002 
Biotin 0.000002 Thiamine hydrochloride 0.0004 
Calcium pantothenate 0.0004 Boric acid 0.0005 
Folic acid 0.00002 Copper  sulphate 0.00004 
Inositol 0.002 Potassium iodide 0.0001 
Ferric chloride 0.0002 Manganese sulphate 0.0004 
Sodium molybdate 0.0002 Zinc sulphate 0.0004 
Monopotassium phosphate 1.000 Magnesium sulphate 0.500 
Sodium chloride 0.10 Calcium chloride 0.100 
Dissolve  6.7gms  of  media  in  100 ml   0f  distilled  water. Serilise  byfilteration  and  
store  at  4 degcelcius. 
 
3.CHROM   AGAR CANDIDA  MEDIUM: 
INGREDIENTS   GMS/L 
Peptone,                                   15 gms 
Yeast extract  4 gms 
Dipotassium hydrogen phosphate 1.gms 
Chromogenic mixture                         7.22 gms 
Chloramphenicol                                 0.5 gms 
Agar                                                     15 gms 
pH  6.3±0.2  at  25°C 
 
Suspend 42.72 grams in 1000 ml distilled water. Heat to boiling to dissolve the medium 
completely. DO NOT AUTOCLAVE. Cool to 45-50°C. Mix well and pour into sterile 
Petri plates. 
 
4. MUELLER  HINTON AGAR: 
 
Ingredients                                 Gms / Litre 
Beef infusion                              300ml 
Casein  hydrosylate 17.5gm 
Starch                                           1.5gm 
Agar                                             10gm 
Final pH     7.4±0.1  
Sterilize  by  autoclaving   at  121°C  for 15 minutes 
 
  
ANNEXURE –I 
CERTIFICATE OF APPROVAL 
 
ANNEXURE –II 
PROFORMA 
  Name :                                                                      IP  NO: 
  Age:                                                                          Ward: 
  Sex: 
  Occupation: 
  Address: 
  Presenting complaints 
  Personal history 
  Past history 
  Prior antibiotic  therapy 
 
 
  Clinical Diagnosis: 
 
  Microbiological  investigation: 
  KOH mount: 
  Direct Gram staining : 
  Culture : Sabouraud dextrose agar: 
   Corn meal agar: 
   Sugar Assimilation and Fermentation test : 
  Organism identified/Speciation: 
Antifungal sensitivity pattern - 
Efficacy of Echinocandins: 
(FOR AZOLE RESISTANT) 
 
  
ANNEXURE –III 
PATIENTS CONSENT FORM 
 
STUDY TITLE : ISOLATION AND CHARACTERISATION OF 
CANDIDA SPECIES FROM POST RENAL TRANSPLANT RECIPIENTS 
WITH URINARY TRACT INFECTION  WITH SPECIAL REFERENCE 
TO ECHINOCANDINS  IN A TERTIARY CARE HOSPITAL”  
 
 I…………………………………………, hereby give consent to 
participate in the study conducted  by Dr.G.ARTHY, Post graduate at Institute of 
Microbiology, Madras Medical College, Chennai and to use my personal clinical 
data and the result of investigations for the purpose of analysis and to study the 
nature of the disease, I also give consent to give my clinical Specimen ( urine) for 
further investigations. I also learn that there is no additional risk in this study. I 
also give my consent for my investigator to publish the data in any forum or 
journal. 
 
   
Signature/ Thumb impression                                   Place                             Date 
Of the patient/ relative 
 
Patient Name & Address: 
 
Signature of the investigator: 
 
  Signature of guide: 
 
ANNEXURE –IV  
INFORMATION SHEET 
 
STUDY TITLE : ISOLATION AND CHARACTERISATION OF CANDIDA 
SPECIES FROM POST RENAL TRANSPLANT RECIPIENTS WITH URINARY 
TRACT INFECTION  WITH SPECIAL REFERENCE TO ECHINOCANDINS  
IN A TERTIARY CARE HOSPITAL”  
 
INVESTIGATOR  : Dr.G.ARTHY, 
                          Post Graduate,     
    Institute of Microbiology, 
    Madras Medical College, 
    Chennai - 600003 
 
GUIDE   : Dr.R.VANAJA M.D., 
                                Professor of Microbiology, 
                                 Institute  of  Microbiology, 
                                Madras  Medical  College, 
                                 Chennai - 600003 
 
  
I am going to detect the susceptibility  ofEchinocandins for Azole resistant 
candida species from Post- Renal transplant patients with Urinary tract infection  in this 
tertiary hospital. I am going to collect  Urine samples for this study and process them 
accordingly.100 patients are included in this study after getting informed consent only. 
This study is entirely voluntary and patient can withdraw any time from this study. Extra 
cost will not be incurred to the patients in this study. Any doubt regarding this study will 
be willingly clarified. Results of the study will be published. In case of any doubt please 
contact Dr. G.ARTHY, Cell: 9787901086 
 
 
 
1 40 M CCMSU Cadaver R R R S
2 35 M CCMSU Live R R R R
3 26 M CCMSU Live
4 45 M CCMSU Cadaver
5 38 M CCMSU Cadaver
6 60 M CCMSU Cadaver R R R R
7 42 M CCMSU Live
8 39 M CCMSU Cadaver S S S S
9 46 M CCMSU Live
10 25 F CCMSU Live S S R S
11 28 F CCMSU Cadaver
12 52 F CCMSU Cadaver R R R S
13 28 F CCMSU Cadaver
14 30 M CCMSU Cadaver
15 26 M CCMSU Cadaver
16 36 M CCMSU Live
17 45 M CCMSU Cadaver
18 35 M CCMSU Live
19 29 M CCMSU Cadaver S S S R
20 38 F CCMSU Cadaver
21 50 M CCMSU Live
22 60 M CCMSU Cadaver R R R S
23 46 M CCMSU Cadaver
24 25 M CCMSU Live
25 45 M CCMSU Live
26 52 M CCMSU Cadaver
27 60 M CCMSU Live S S S R
28 50 F CCMSU Live
29 28 M CCMSU Cadaver
30 29 M CCMSU Cadaver
31 31 M CCMSU Cadaver
32 29F F CCMSU Live
33 39 M CCMSU Live R R R S
34 40 M CCMSU Live
35 26 M CCMSU Cadaver
Krishnamoorthy
Anbumani
Gowtham
Bhuvaneshwari
Sathish Kumar
Kumar
Kalidass
Arumugam
Purushothaman
Vinoth
Karthik
Rekha
Mohammed Ali
Sathiyaraj
Gayathri
Immanuvel
Munnusamy
Senthilkumar
Baskar
S. 
NO.
Name Age sex
Urine 
sample 
collection
Live / 
Deceased
Chandrababu
Maruthanidhi
Manikandan
Ravichandran
Dhanasekar
Arivazhagan
Selvakumari
Kamali
Kaleeswari
Prakash
Moideen Kadar
Gowtham
S
S
S
S
S
S
+
+
+
+
+
+
C.glabrata x 10⁵
No growth
No growth
No growth
No growth
No growth
No growth
No growth
No growth
No growth
No growth
No growth
C.tropicalis x 10⁵
No growth
C.albicans x 10⁵
No growth
No growth
C.glabrata x 10⁵
No growth
No growth
No growth
No growth
No growth
<1WBC/7HPF
<1WBC/7HPF
>1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
>1WBC/7HPF
>1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
>1WBC/7HPF
<1WBC/7HPF
>1WBC/7HPF
<1WBC/7HPF
>1WBC/7HPF
<1WBC/7HPF
>1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
clear
clear
clear
clear
turbid
symptomatic
Asympomatic
Asympomatic
Asympomatic
symptomatic
Asympomatic
symptomatic
Asympomatic
symptomatic
Asympomatic
symptomatic
symptomatic
Asympomatic
Asympomatic
clear
clear
symptomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
turbid
clear
>1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
Asympomatic
Asympomatic
Asympomatic
Asympomatic
clear
clear
clear
clear
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
Asympomatic
symptomatic
Asympomatic
Asympomatic
symptomatic
clear
turbid
clear
clear
turbid >1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
>1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
clear
clear
clear
clear
clear
<1WBC/7HPF
turbid
clear
turbid
clear
turbid
C.albicans x 10⁵
No growth
C.tropicalis x 10⁵
No growth
C.krusei x 10⁵
<1WBC/7HPF
Murugesan
clear
clear
clear
turbid
clear
No growth
No growth
No growth
C.krusei x 10⁵
No growth
ECHINO 
CANDINS
VISIT 1
turbid
turbid
C.albicans x 10⁵
C.glabrata x 10⁵
symptomatic
symptomatic/Asympo
matic
Macroscopy wet  film
Selvaraj
Vinoth Antony
Selvam
GROWTH FLU ITR VOR NYS BBiofilm
S. 
NO.
Name Age sex
Urine 
sample 
collection
Live / 
Deceased ECHINO 
CANDINS
VISIT 1
symptomatic/Asympo
matic
Macroscopy wet  film GROWTH FLU ITR VOR NYS BBiofilm
36 25 F CCMSU Cadaver
37 35 F CCMSU Live
38 29 M CCMSU Cadaver S R S S
39 36 F CCMSU Cadaver
40 38 M CCMSU Cadaver
41 41 F CCMSU Cadaver
42 60 M CCMSU Cadaver
43 25F F CCMSU Cadaver
44 21 M CCMSU Live
45 39 M CCMSU Cadaver
46 41 M CCMSU Live
47 29 M CCMSU Cadaver
48 50 M CCMSU Live R R R R
49 29 M CCMSU Cadaver S S R S
50 60 M CCMSU Live
51 52 F CCMSU Live
52 51 F CCMSU Live
53 26 F CCMSU Live
54 29 M CCMSU Live
55 28 M CCMSU Live
56 22 M CCMSU Live
57 26 M CCMSU Live
58 29F F CCMSU Live
59 23 F CCMSU Cadaver S S S R
60 25 M CCMSU Live
61 32 F CCMSU Live
62 30 F CCMSU Cadaver
63 27 M CCMSU Cadaver R S S S
64 33 M CCMSU Live
65 28 F CCMSU Cadaver
66 60 M CCMSU Cadaver
67 30 M CCMSU Live
68 25 M CCMSU Live R S S S
69 41 M CCMSU Live
70 41 M CCMSU Live
Karthika
Marialouis
Kaleesha
Karthikeyan
Poornaporkodi
Bharathi
Kumaraguru
Hariprasath
Kishore Gowtham
Sathasivam
Senthilkumar
Dhanush
Bakiya Lakshmi
Meena
Rajini
Sivakumar
Murugan
Vignesh
Parthiban
Shainisha
Kaviyarasu
Ragavendra kumar
S+
C.albicans x 10⁵
No growth
No growth
C.albicans x 10⁵
No growth
No growth
No growth
No growth
No Growth
C.tropicalis x 10⁵
No Growth
No Growth
No Growth
C.albicans x 10⁵
No Growth
No Growth
No Growth
No Growth
C.glabrata x 10⁵
C.parapsilosis x 10⁵
No Growth
No Growth
No Growth
No growth
No growth
No growth
No growth
No growth
C.albicans x 10⁵
No growth
No growth
No growth
No growth
No growth
No growth
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
>1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
>1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
>1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
>1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
>1WBC/7HPF
>1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
clear
clear
clear
clear
clear
clear
turbid
turbid
clear
clear
clear
turbid
clear
clear
clear
clear
clear
turbid
clear
clear
clear
turbid
clear
clear
clear
clear
turbid
clear
clear
clear
clear
clear
Asympomatic
symptomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
symptomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
symptomatic
Asympomatic
Asympomatic
Hemalatha
symptomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
symptomatic
Asympomatic
Asympomatic
Asympomatic
Valter Vetrivel
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
sympomatic
symptomatic
Asympomatic
Asympomatic
Asympomatic
Brindha
Manikandan
Prakash
Alagusundar
Yasmin
Ashok Matha
Maivannan
Jafardeen
Veeravel
Prabakaran
Loganathan
clear
turbid
Asympomatic clear <1WBC/7HPF
<1WBC/7HPF
>1WBC/7HPF
S. 
NO.
Name Age sex
Urine 
sample 
collection
Live / 
Deceased ECHINO 
CANDINS
VISIT 1
symptomatic/Asympo
matic
Macroscopy wet  film GROWTH FLU ITR VOR NYS BBiofilm
71 41 M CCMSU Cadaver
72 47 M CCMSU Cadaver
73 36 M CCMSU Live
74 44 F CCMSU Live
75 20 M CCMSU Cadaver S S S S
76 37 M CCMSU Cadaver
77 32 M CCMSU Live
78 43 F CCMSU Cadaver
79 37 F CCMSU Live
80 41 M CCMSU Live S S R S
81 39 M CCMSU Cadaver
82 37 M CCMSU Cadaver
83 30 M CCMSU Live
84 37 F CCMSU Cadaver
85 28 M CCMSU Cadaver S R S S
86 40 M CCMSU Cadaver
87 43 M CCMSU Live
88 42 M CCMSU Cadaver
89 49 M CCMSU Live
90 46 M CCMSU Live
91 52 F CCMSU Cadaver
92 39 M CCMSU Cadaver
93 42 F CCMSU Cadaver
94 34 F CCMSU Cadaver S S S S
95 37 F CCMSU Cadaver
96 29 F CCMSU Cadaver
9 39 F CCMSU Cadaver
98 41 F CCMSU Live
99 45 F CCMSU Live
100 48 F CCMSU Live
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
symptomatic
Asympomatic
Asympomatic
Geetha
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
symptomatic
Asympomatic
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
>1WBC/7HPF
Senthamizh Selvan
Venkatesh
Bose
Rajamani
Irfan
Marudhanidhi
Arunkumar
Manjula
Kalavathy
Ramesh
Ramanujam
Kamali
Saravanan
Moideen Basha
Murugan
Lakshmanan
Elumalai
Prabhu
Alicerajakumari
Balakrishnan
clear
usha
Dharani
clear
clear
clear
clear
clear
turbid
No growth
No growth
No growth
No growth
No growth
No growth
C.albicans x 10⁵
No growth
No growth
No growth
No growth
No growth
No growth
C.albicans x 10⁵
No growth
No growth
No growth
No growth
No growth
No growth
No growth
No growth
No growth
No growth
C.albicans x 10⁵
No growth
No growth
No growth
No growth
C.albicans x 10⁵
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
>1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
>1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
>1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
clear
turbid
clear
clear
clear
clear
clear
clear
clear
clear
clear
turbid
clear
clear
clear
clear
turbid
clear
clear
clear
clear
clear
clearAsympomatic
Asympomatic
sympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
symptomatic
Asympomatic
Asympomatic
Anand
Asympomatic
Asympomatic
Maria
sangeetha
roja
sumathi
Rani
Ravi
Asympomatic
1 40 M CCMSU Cadaver R R R S
2 35 M CCMSU Live
3 26 M CCMSU Live
4 45 M CCMSU Cadaver S R S S
5 38 M CCMSU Cadaver
6 60 M CCMSU Cadaver
7 42 M CCMSU Live
8 39 M CCMSU Cadaver S S S S
9 46 M CCMSU Live
10 25 F CCMSU Live
11 28 F CCMSU Cadaver
12 52 F CCMSU Cadaver
13 28 F CCMSU Cadaver
14 30 M CCMSU Cadaver
15 26 M CCMSU Cadaver
16 36 M CCMSU Live
17 45 M CCMSU Cadaver S R S S
18 35 M CCMSU Live
19 29 M CCMSU Cadaver
20 38 F CCMSU Cadaver
21 50 M CCMSU Live S S S S
22 60 M CCMSU Cadaver
23 46 M CCMSU Cadaver R R R S
24 25 M CCMSU Live
25 45 M CCMSU Live
26 52 M CCMSU Cadaver R R R R
27 60 M CCMSU Live
28 50 F CCMSU Live
29 28 M CCMSU Cadaver
30 29 M CCMSU Cadaver
31 31 M CCMSU Cadaver S S R S
32 29F F CCMSU Live
33 39 M CCMSU Live
34 40 M CCMSU Live
35 26 M CCMSU Cadaver
VISIT 2
ECHINO 
CANDINS
Bio film FLU ITR VOR NYS B
Urine 
sample 
collection
Gayathri
Immanuvel
Munnusamy
Senthilkumar
Baskar
Dhanasekar
Arivazhagan
Selvakumari
Kamali
Murugesan
Selvaraj
Vinoth Antony
Selvam
Chandrababu
Maruthanidhi
Krishnamoorthy
Anbumani
Gowtham
Kaleeswari
Prakash
Moideen Kadar
Gowtham
Bhuvaneshwari
Sathish Kumar
Kumar
Kalidass
Arumugam
Purushothaman
Vinoth
Karthik
Rekha
Mohammed Ali
Sathiyaraj
S
S
S
+
+
+
No Growth
C.glabrata x 10⁵
No Growth
No Growth
No Growth
No Growth
C.albicans x 10⁵
No Growth
C.krusei x 10⁵
No Growth
No Growth
No Growth
C.tropicalis x 10⁵
No Growth
No Growth
No Growth
No Growth
No Growth
No Growth
No Growth
No Growth
C.albicans x 10⁵
No Growth
No Growth
No Growth
No Growth<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
>1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
>1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
>1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
>1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
>1WBC/7HPF
<1WBC/7HPF
clear
clear
clear
clear
turbid
clear
clear
clear
clear
turbid
clear
clear
clear
clear
turbid
clear
turbid
turbid
clear
clear
clear
turbid
clear
clear
clear
clear
clear
clear
clear
clear
turbid
clear
sex
symptomatic/Asympo
matic
>1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
>1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
>1WBC/7HPF
No Growth
No Growth
No Growth
C.albicans x 10⁵
Asympomatic
Asympomatic
Symptomatic
No Growth
C.albicans x 10⁵
No Growth
No Growth
C.tropicalis x 10⁵
Asympomatic
Asympomatic
Name
Manikandan
Ravichandran
S.NO
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Symptomatic
Asympomatic
Asympomatic
wet  filmMacroscopy GROWTH
Live / 
Deceased
Age 
clear
clear
turbid
Asympomatic
Asympomatic
Asympomatic
Symptomatic
Symptomatic
Asympomatic
Asympomatic
Symptomatic
Asympomatic
Symptomatic
Asympomatic
Asympomatic
Symptomatic
Asympomatic
Asympomatic
Asympomatic
Symptomatic
Asympomatic
Asympomatic
VISIT 2
ECHINO 
CANDINS
Bio film FLU ITR VOR NYS B
Urine 
sample 
collection
sex
symptomatic/Asympo
matic
NameS.NO
wet  filmMacroscopy GROWTH
Live / 
Deceased
Age 
36 25 F CCMSU Cadaver
37 35 F CCMSU Live
38 29 M CCMSU Cadaver S R S S
39 36 F CCMSU Cadaver
40 38 M CCMSU Cadaver
41 41 F CCMSU Cadaver
42 60 M CCMSU Cadaver
43 25F F CCMSU Cadaver S S R R
44 21 M CCMSU Live
45 39 M CCMSU Cadaver
46 41 M CCMSU Live
47 29 M CCMSU Cadaver
48 50 M CCMSU Live
49 29 M CCMSU Cadaver S S S S
50 60 M CCMSU Live
51 52 F CCMSU Live
52 51 F CCMSU Live
53 26 F CCMSU Live
54 29 M CCMSU Live
55 28 M CCMSU Live
56 22 M CCMSU Live
57 26 M CCMSU Live
58 29F F CCMSU Live
59 23 F CCMSU Cadaver
60 25 M CCMSU Live
61 32 F CCMSU Live R R R S
62 30 F CCMSU Cadaver
63 27 M CCMSU Cadaver
64 33 M CCMSU Live
65 28 F CCMSU Cadaver
66 60 M CCMSU Cadaver
67 30 M CCMSU Live
68 25 M CCMSU Live
69 41 M CCMSU Live
70 41 M CCMSU Live
Kishore Gowtham
Sathasivam
Senthilkumar
Rajini
Sivakumar
Hemalatha
Kumaraguru
Hariprasath
Parthiban
Loganathan
Manikandan
Prakash
Alagusundar
Yasmin
Brindha
Maivannan
Jafardeen
Veeravel
Prabakaran
Ragavendra kumar
Karthika
Poornaporkodi
Bharathi
No Growth
No Growth
C.glabrata x 10⁵
No Growth
No Growth
No Growth
No Growth
No Growth
No Growth
No Growth
No Growth
No Growth
Marialouis
Kaleesha
Karthikeyan
Shainisha
Kaviyarasu
Dhanush
Bakiya Lakshmi
Meena
Ashok Matha
Valter Vetrivel
Murugan
Vignesh
No Growth
No Growth
S+
C.parapsilosis x 10⁵
No Growth
No Growth
No Growth
No Growth
No Growth
No Growth
No Growth
No Growth
No Growth
No Growth
No Growth
C.tropicalis x 10⁵
No Growth
No Growth
No Growth
No Growth
No Growth
No Growth
No Growth
C.albicans x 10⁵
<1WBC/7HPF
>1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
>1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
>1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
>1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
clear
clear
clear
clear
clear
clear
clear
clear
clear
turbid
clear
clear
clear
clear
clear
clear
clear
turbid
clear
clear
clear
clear
clear
clear
clear
clear
clear
clear
clear
clear
clear
turbid
clear
clear
turbid
Asympomatic
Symptomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Symptomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Symptomatic
Asympomatic
Asympomatic
Asympomatic
Symptomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
VISIT 2
ECHINO 
CANDINS
Bio film FLU ITR VOR NYS B
Urine 
sample 
collection
sex
symptomatic/Asympo
matic
NameS.NO
wet  filmMacroscopy GROWTH
Live / 
Deceased
Age 
71 41 M CCMSU Cadaver
72 47 M CCMSU Cadaver
73 36 M CCMSU Live
74 44 F CCMSU Live
75 20 M CCMSU Cadaver
76 37 M CCMSU Cadaver
77 32 M CCMSU Live
78 43 F CCMSU Cadaver
79 37 F CCMSU Live
80 41 M CCMSU Live S R S S
81 39 M CCMSU Cadaver
82 37 M CCMSU Cadaver
83 30 M CCMSU Live
84 37 F CCMSU Cadaver
85 28 M CCMSU Cadaver
86 40 M CCMSU Cadaver
87 43 M CCMSU Live
88 42 M CCMSU Cadaver
89 49 M CCMSU Live
90 46 M CCMSU Live
91 52 F CCMSU Cadaver
92 39 M CCMSU Cadaver
93 42 F CCMSU Cadaver
94 34 F CCMSU Cadaver
95 37 F CCMSU Cadaver S S S R
96 29 F CCMSU Cadaver
97 39 F CCMSU Cadaver
98 41 F CCMSU Live
99 45 F CCMSU Live
100 48 F CCMSU Live
No Growth
No Growth
No Growth
C.albicans x 10⁵
No Growth
No Growth
No Growth
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
No Growth
No Growth
No Growth
No Growth
No Growth
>1WBC/7HPF
<1WBC/7HPF
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Symptomatic
Asympomatic
Asympomatic
Asympomatic
Geetha
Rani
sumathi
roja
sangeetha
Prabhu
Alicerajakumari
Balakrishnan
Anand
Arunkumar
Lakshmanan
Elumalai
Maria
usha
Dharani
Murugan
Moideen Basha
Saravanan
Kamali
Senthamizh Selvan
Bose
Rajamani
Irfan
Marudhanidhi
Ravi
Manjula
Kalavathy
Ramesh
Ramanujam
Venkatesh
No Growth
No Growth
No Growth
No Growth
No Growth
No Growth
No Growth
No Growth
C.albicans x 10⁵
No Growth
No Growth
No Growth
No Growth
No Growth
No Growth
No Growth
No Growth
No Growth
Asympomatic
Asympomatic
Asympomatic
Asympomatic
clear
clear
clear
turbid
clear
clear
clear
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
>1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
clear
clear
clear
clear
clear
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
<1WBC/7HPF
clear
clear
clear
clear
clear
clear
turbid
clear
clear
clear
clear
clear
clear
clear
clear
clear
clear
clear
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Symptomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
Asympomatic
